Amphista Therapeutics received FDA IND clearance for AMX-883, an orally bioavailable BRD9 degrader, for treatment of acute myeloid leukemia (AML). The company said a Phase 1 trial for patients with relapsed or refractory AML and high-risk myelodysplastic syndrome is expected to begin in the second half of the year. AMX-883 is designed as a targeted protein degradation approach against BRD9, a gene involved in transcriptional regulation through chromatin remodeling pathways. Amphista framed the IND clearance as a step toward translating its degrader design into a clinical efficacy and safety evaluation. The initiation timeline places AMX-883 among the next wave of degrader candidates seeking to establish early clinical differentiation in hematologic malignancies. For investors, IND clearance remains a key milestone that can accelerate partnership and follow-on financing. The clearance also highlights continuing FDA openness to targeted degradation mechanisms in oncology, particularly when programs target well-defined chromatin-dependent biology.